in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at GSK, KV Pharmaceutical, ParagonRx, West, Novavax and Unilife.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Almac, BioStorage Technologies and ACM Global.
In a busy week of Big Phama results Pfizer reports sales boost from Wyeth, Roche says Genentech hit profits and GSK unveils surge in Relenza sales and plans to expand R&D restructuring.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including Cel-Sci strengthening its manufacturing team and three promotions at Adolor.
Indian API maker Avon Organics’ share price rocketed 10 per cent on the Bombay exchange yesterday after the US launch of a generic herpes treatment by Ranbaxy Laboratories.
The drug industry must “fundamentally change” how it sells products and make greater use of advanced analytics to measure performance, according to a report by Deloitte Consulting.
Bias in publications in medical journals is facing intense scrutiny again, following media reports GSK used a ghostwriting programme and separate research into combating the problem.
GlaxoSmithKline’s (GSK) $2.9bn (€1.8bn) cash acquisition of US skin drug specialist Stiefel Laboratories “re-energises” the UK firm’s dermatology range, according to CEO Andrew Witty.
The pharmaceutical rumour mill is still spinning with the latest speculation that UK drug major GSK is interested in Botox manufacturer Allergan causing the US firm’s share price to leap 13 per cent on the New York Stock Exchange.
Two approvals in a week for drugs made at Ranbaxy’s New Jersey OHM Laboratories subsidiary have eased the generics firm’s North American regulatory woes and strengthened its position in the expanding US market.
Indian IT company Satyam continues to be rocked by the fraud scandal, with media reports claiming that GSK and Novartis are on the verge of taking their business elsewhere.
GlaxoSmithKline has gone into partnership with Indian contract manufacturing and development services company Kemwell to set up an R&D facility aimed at developing new oral healthcare products.
UK drug giant GSK is to shed 200 jobs at its manufacturing plant in Barnard Castle, County Durham to cut costs ahead of generic competition for products made at the facility, which include the anti-emetic Zofran (ondansentron).
GlaxoSmithKline (GSK) has proposed that it will close its facility in Dartford, UK in 2013, as the loss of patents for key drugs makes its operation uneconomical.
UK drug major GSK is cutting approximately 1,000 US sales jobs by the end of 2008 as it reorganizes to compete in the increasingly tough pharmaceutical market.
Data analysis may be the next aspect of the drug industry to be outsourced if the new virtual drug development network created by GSK and UK software firm InforSense is any indication.
GlaxoSmithKline (GSK) has sold four of its off-patent drug products
to a South African drugmaker for £170m ($336m), describing the move
as part of an ongoing effort to simplify its manufacturing
operations.
UK drug major GlaxoSmithKline is examining operations at its active
pharmaceutical ingredient (API) manufacturing plant in Montrose,
Scotland, with an eye to potential job cuts.
Flamel Technologies has yet again experienced a net loss of $37.2m
for 2007, following a string of bad fortune in 2005 and 2006, but
believes it may be about to turn the corner.
A UK chemicals plant has become the latest casualty of
GlaxoSmithKline's (GSK's) pledge to make the business leaner with
the help of outsourcing and offshoring.
While GSK, AstraZeneca and Eli Lilly have hit the headlines in the
UK Serious Fraud Office's (SFO) investigation into illegal bribes
paid to Saddam Hussein's Iraqi regime, many more pharma firms are
on the organisation's...
Pfizer's revelation this week that it plans to slice jobs in Puerto
Rico is the latest in a string of blows for this popular offshore
manufacturing location.
GlaxoSmithKline (GSK) has been swift in implementing its plant
cuts, already announcing the first sites to be axed mere hours
after revealing its restructuring plans.
GlaxoSmithKline (GSK) has emerged as the latest pharma firm to
announce closures and job cuts along with its third quarter
results, yet another casualty of generic competition and product
safety scares.
Celsis' Rapid Microbiological Method (RMM) has been included in GlaxoSmithKline's (GSK) successful Veramyst New Drug Application (NDA), paving the way for broader acceptance of the time saving technique.
UK firm SkyePharma last week announced that the US Food and Drug
Administration (FDA) has accepted a filing for the extended release
formulation of partner GlaxoSmithKline's (GSK) drug Requip
(ropinirole).
A new rapidly dissolving oral strip for ondansetron, the active
ingredient in GSK's anti-emetic drug Zofran, has been developed in
a Swiss-German collaboration.
Major pharmaceutical player GlaxoSmithKline (GSK) has begun
construction of a €23m facility in County Waterford, Ireland. The
new facility is already under construction at the company's
consumer healthcare manufacturing site...
Offshoring contract manufacturing is not the only option for large
pharma firms looking to drive productivity and efficiency gains in
drug manufacturing, warns a new report from independent market
analyst Datamonitor.
GlaxoSmithKline (GSK) publishes its fourth quarter earnings, which
indicate a significant profit rise well ahead of industry
predictions, with momentum building in its product pipeline of new
drugs giving the company the go-ahead...
Troubled firm Flamel reported a sharp decrease in total third
quarter revenues - $3.1 million (€2.6 million), compared to $13.3
million this time last year - resulting in a net loss $11.9
million.
A recently published report has revealed that less than 13 per cent
of US consumers believe that information provided by pharmaceutical
companies is more trustworthy than healthcare information provided
by other organisations.
A suite of optical detection methods, developed by Finnish
researchers alongside world number two drugmaker GlaxoSmithKline,
promises to cut the cost of drug production and increase the safety
and quality of medicinal products.
French drug delivery company Flamel Technologies suffered another
blow yesterday when it was revealed that TAP Pharmaceutical
Products has pulled out of deal to develop a formulation of its
big-selling gastrointestinal drug lansoprazole...
UK-headquartered pharma giant GlaxoSmithKline says it has overcome
the manufacturing problems that caused it to voluntarily withdraw
its antidepressant Paxil CR (paroxetine) and diabetes drug
Avandamet (metformin and rosiglitazone)...
The founder, chairman and chief executive of French drug delivery
company Flamel Technologies has been lambasted by disgruntled
shareholders who want to bring in a new management team, writes
Phil Taylor.
According to a new report, the US pharmaceutical industry is
ignoring as much as $16 billion (€13 billion) in cash as the
industry struggles to cope with disappointing single-digit growth,
a lack of new products to replace drugs coming...
Singapore contract biologics manufacturer A-Bio has added another
top pharmaceutical company to its list of customers, just over 18
months after starting operations, reports Phil Taylor.
GlaxoSmithKline has signed a consent decree with the US Food and
Drug Administration to correct manufacturing deficiencies at its
Cidra, Puerto Rico facility, but could be in a position to return
two drugs made at the plant to market...
There is speculation that the problems at GlaxoSmithKline's
manufacturing facility in Puerto Rico may prove to be more costly
for the company than originally thought.
Johnson & Johnson is planning to acquire TransForm
Pharmaceuticals, a privately held company that specialises in the
discovery of improved formulations and novel crystalline forms of
drug molecules, in a cash-for-stock deal valued...
UK company SkyePharma has shrugged off the news that production of
a GlaxoSmithKline drug based on its drug delivery technology, the
antidepressant Paxil CR (paroxetine), had been halted by the US
Food and Drug Administration (FDA).
Figures released by the Association of the British Pharmaceutical
Industry (ABPI) has revealed that the level of intimidation posed
by animal extremists reaches as far as the suppliers who do
business with companies involved with...
New laws to stop increasingly violent animal extremists from
harassing scientists involved in medical experiments have received
the seal of approval by the Association of the British
Pharmaceutical Industry (ABPI).
A number of measures to help make the UK Medicines and Healthcare
Products Regulatory Authority (MHRA) and the pharmaceutical
industry operate more openly and transparently were announced late
last week by the country's Health...
